Search for stocks /

Kilitch Drugs (India) Ltd: From Ethiopia With Love – Pharma’s Export-Heavy Dark Horse


1. At a Glance

Kilitch Drugs (KDL) is not your average Indian pharma – it makes injectables, oral formulations, herbal products, AND even a CE-certified medical device. With a strong African footprint (hello Ethiopia), sales are climbing at 30% CAGR over 5 years, and PAT at 164% CAGR. But the latest quarterly results show the classic pharma rollercoaster – revenue up 29% YoY, profit up 126%, yet margins acting like a moody doctor who prescribes antibiotics for viral flu.


2. Introduction

Founded in 1978, KDL started small in Mumbai but has built itself into a mid-sized pharma player with exports forming nearly 60% of revenue. While big brothers like Sun Pharma and Cipla roam the US generics battlefield, KDL chose a different hunting ground – Africa. It has a fully operational facility in Ethiopia making cephalosporins and winning government supply tenders worth USD 9.1 million. Smart move – where competitors are fighting over ANDAs in the US, Kilitch is the local pharmacy kingpin in Addis Ababa.

But before you imagine it as the next Lupin, let’s be real: this is still a ₹643 Cr company versus Sun Pharma’s ₹3.8 lakh Cr. The difference between them? Sun is in the Formula 1 of pharma, Kilitch is still kart-racing but speeding up.

Also, the company is splurging ₹100 Cr on a greenfield Khopoli facility (to be operational by 2025). Rights issue? Already approved. Dilution? Of course. But hey, at least they’re not pledging shares like a soap opera villain.

So, should one clap for Kilitch’s African safari or worry about its Indian domestic lag?


3. Business Model – WTF Do They Even Do?

Kilitch is into formulation manufacturing across five categories:

  • Parenterals & Nasal – injectables, dry powders, nasal drops for everything from malaria to uterine stimulation. Basically, “if it can be injected, we’ll sell it.”
  • Orals & Nutraceuticals – tablets, capsules, powders, antibiotics, anti-diabetics, cardiovascular drugs. Standard pharma thali.
  • Effervescents – fizzy tablets/powders (think ENO, but with a prescription).
  • Medical Device – C-SEAL, a CE-certified topical adhesive. Because why not?
  • Herbal & Cosmetics – oils, lotions, supplements for libido, diabetes, prostate… one stop shop for your body and soul.

Its Ethiopia subsidiary (Kilitch Estro Biotech) gives it a strong government-backed pharma supply channel in Africa. And Ethiopia isn’t a one-off – KDL exports to Asia, CIS, and Latin America too.

Clients? Biggies like Mankind, Shalina, Ava Care, Indoco Remedies. Not bad for a ₹200 Cr sales company.


4. Financials Overview

Source table
MetricLatest Qtr (Q1 FY26)YoY Qtr (Q1 FY25)Prev Qtr (Q4 FY25)YoY %QoQ %
Revenue₹43.1 Cr₹33.4 Cr₹61.2 Cr29.0%-29.6%
EBITDA₹3.3 Cr₹1.7 Cr₹14.6 Cr95.0%-77.5%
PAT₹3.03 Cr₹1.34 Cr₹10.2 Cr126%-70.4%
EPS (₹)1.730.775.94124%-70.9%

Annualised EPS = 1.73 × 4 = ₹6.9
At CMP ₹368 → Forward P/E ≈ 53x (ouch).

Commentary: Strong YoY bounce, but QoQ slump. Typical of a company dependent on tenders and lumpy exports.


5. Valuation – Fair

Join 10,000+ investors who read this every week.
Become a member
error: Content is protected !!